|
UBQLN4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.36044517265555E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.42680000037032E-08 |
| Normal-vs-Stage2 |
1.085730E-02 |
| Normal-vs-Stage3 |
9.37690000091251E-08 |
| Normal-vs-Stage4 |
2.89200000003209E-06 |
| Stage1-vs-Stage2 |
5.320800E-01 |
| Stage1-vs-Stage3 |
1.123210E-01 |
| Stage1-vs-Stage4 |
8.444200E-03 |
| Stage2-vs-Stage3 |
1.320220E-01 |
| Stage2-vs-Stage4 |
7.459300E-03 |
| Stage3-vs-Stage4 |
8.780400E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.64654964610145E-12 |
| Normal-vs-AfricanAmerican |
9.987200E-04 |
| Normal-vs-Asian |
1.180770E-04 |
| Caucasian-vs-AfricanAmerican |
1.541050E-01 |
| Caucasian-vs-Asian |
2.151200E-01 |
| AfricanAmerican-vs-Asian |
9.073800E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.30599999999637E-05 |
| Normal-vs-Female |
5.17397236166062E-12 |
| Male-vs-Female |
8.655600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.06659999615988E-08 |
| Normal-vs-Age(41-60Yrs) |
1.68529999955425E-07 |
| Normal-vs-Age(61-80Yrs) |
3.06490000046011E-07 |
| Normal-vs-Age(81-100Yrs) |
6.279700E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.821000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.205800E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.302000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.768220E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.919600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.972400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.179400E-01 |
| Classical-VS-Follicular |
6.88338275267597E-15 |
| Classical-VS-Other |
1.840190E-01 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
3.36909999998358E-06 |
| Tall-VS-Other |
9.238500E-02 |
| Tall-VS-Normal |
2.09659999999001E-05 |
| Follicular-VS-Other |
2.251600E-01 |
| Follicular-VS-Normal |
3.455000E-01 |
| Other-VS-Normal |
3.842800E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.59024999999424E-05 |
| Normal-vs-N1 |
1.035330E-04 |
| N0-vs-N1 |
1.190650E-01 |
|
|
